Answers are grounded in this paper and cite their sources.
HBV reactivation occurred in 4.6% of RA patients with resolved HBV during the treatment with bDMARDs and the absence of anti-HBs may be a risk factor for the reactivation of resolved HBV.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: